<SEC-DOCUMENT>0001213900-23-087912.txt : 20231116
<SEC-HEADER>0001213900-23-087912.hdr.sgml : 20231116
<ACCEPTANCE-DATETIME>20231116160508
ACCESSION NUMBER:		0001213900-23-087912
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20231116
FILED AS OF DATE:		20231116
DATE AS OF CHANGE:		20231116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NLS Pharmaceutics Ltd.
		CENTRAL INDEX KEY:			0001783036
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39957
		FILM NUMBER:		231414587

	BUSINESS ADDRESS:	
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		STATE:			V8
		ZIP:			CH-6370
		BUSINESS PHONE:		41-41-618-80-00

	MAIL ADDRESS:	
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		STATE:			V8
		ZIP:			CH-6370
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea188582-6k_nlspharma.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of November 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-39957</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>NLS PHARMACEUTICS LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The Circle 6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>8058 Zurich, Switzerland</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Auditor Communication </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">On November
10, 2023, </FONT>NLS Pharmaceutics Ltd., or the Company, received a letter, or the Letter, from its independent auditor, PricewaterhouseCoopers
AG, or the Auditor. The Letter, which was issued pursuant to Art. 725 and Art. 725b par. 1 of the Swiss Code of Obligations, requested
that the Company provide a balance sheet at going concern and liquidation values as of October 31, 2023, to assess whether the Company&rsquo;s
equity shows an excess of liabilities over assets, with such balance sheet required to be provided no later than November 20, 2023. The
Auditor advised it was issuing the Letter, in part, due to the fact that it has been advised that the Company will not have sufficient
cash to fund its operations through December 31, 2023. In the event that the balance sheet confirms the Auditor&rsquo;s concern of the
Company&rsquo;s over-indebtedness, the Company&rsquo;s Board of Directors will be obligated to notify a Swiss judge, unless the Company
can otherwise show it is able to meet its financial obligations. If the Company does not provide the requested balance sheet information,
the Auditor will be legally obligated to notify a Swiss judge of the over-indebtedness pursuant to Art. 728c par. 3 of the Swiss Code
of Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Bridge Loans </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">On November 15, 2023,
the Company entered into a series of short term loan agreements, or the Loan Agreements, with certain existing shareholders of the Company,
including Ronald Hafner, the Company&rsquo;s Chairman of the Board of Directors, Felix Grisard, J&uuml;rgen Bauer and Maria Nayvalt, or
the Lenders, providing for an unsecured loan to the Company in the aggregate amount of CHF 875,000.00 (approximately $1,000,000.00), or
the Loan. Pursuant to the Loan Agreements, the Loans bear interest at a rate of 10% per annum and mature on the earlier of June 30, 2024
or a liquidity event with a strategic partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The Company believes that
the proceeds of the Loan will resolve the issues raised by the Auditor in the Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">In addition, the Company
and Mr. Hafner agreed to extend the maturity of the previous short term loan of <FONT STYLE="background-color: white">CHF 500,000 that
Mr. Hafner extended to the Company on September 28, 2023, such that it now expires on June 30, 2024. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The foregoing summary
of the Loan Agreements does not purport to be complete and is qualified in its entirety by reference to the Loan Agreements, a form of
which is attached as Exhibit 99.1 to this report, and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Press Release</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">The
Company issued a press release titled: &ldquo;NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge
Loan.&rdquo; A copy of this press release is furnished herewith as exhibit 99.2.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report of Foreign Private Issuer on Form 6-K
is incorporated by reference into the Company&rsquo;s Registration Statements on Form F-3 (File Nos. <A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390022005236/ea154797-f3_nlspharma.htm">333-262489</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390022077965/ea169650-f3_nlspharm.htm">333-268690</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390023002775/ea171509-f3_nlspharm.htm">333-269220</A>),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 90%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea188582ex99-1_nlspharma.htm">Form of Short
    Term Loan Agreement</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>99.2</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea188582ex99-2_nlspharma.htm">Press Release Titled: NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan</A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NLS Pharmaceutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 16, 2023</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alexander Zwyer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander Zwyer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea188582ex99-1_nlspharma.htm
<DESCRIPTION>FORM OF SHORT TERM LOAN AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Loan Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&ldquo;<B>Agreement</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">November 15, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NLS
Pharmaceutics AG</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Circle 6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8058
Z&uuml;rich</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Switzerland</FONT></TD><TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Borrower</B>&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[&nbsp;&nbsp;]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&nbsp;&nbsp;]</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&nbsp;&nbsp;]</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left">[&nbsp;&nbsp;]</TD><TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Lender</B>&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Borrower
and Lender each a &ldquo;<B>Party</B>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collectively
the &ldquo;<B>Parties</B>&rdquo;)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Loan Agreement</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; width: 10%; font-size: 10pt">2/4</TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Loan Amount</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in">The Lender herewith grants a loan to the Borrower in
the amount of CHF 250,000.00 (&ldquo;<B>Loan</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in">The Loan shall be paid out within 5 Business Days after the execution of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in">The Loan shall be transferred to an account designated by the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Interest</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: left">The Loan shall bear interest
at the rate of 10% <I>per annum</I>, calculated from (and including) the date of receipt of the Loan on the bank account designated
by the Borrower to (and including) the Maturity Date (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: left">Interest is calculated on the basis of the exact number of
days in relation to a year of 360 days (actual/360).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: left">Interest shall be accrued and only becomes due and payable, together with the
principal Loan amount, at the Maturity Date (or the date of its earlier repayment and/or conversion) to the bank account indicated
by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Purpose</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: left">The Loan shall be used by
the Borrower for general financing and corporate purposes in accordance with the purpose of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Term, Maturity, Repayment</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: left">This Agreement enters into
effect on November 15, 2023. The loan will become due and payable on the earlier of (i) June 30, 2024 or (ii) a liquidity event with a
strategic partner. (&ldquo;<B>Maturity Date</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify">The entire Loan including
accrued and unpaid interest shall become due for repayment on the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">Collateral</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify">The Loan shall not be secured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify">MISCELLANEOUS</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><B>6.1.</B></TD><TD STYLE="text-align: justify"><B>Confidentiality</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">The existence as well as
the terms and conditions of the Agreement, and any information exchanged among the Parties in connection with the Agreement (all such
information collectively &ldquo;<B>Confidential Information</B>&rdquo;), shall be kept strictly confidential by each Party. The Parties
shall neither use in any form nor disclose to any third party any Confidential Information unless explicitly authorized by this Agreement.
The Parties shall ensure that their employees, directors and any other representatives as well as the advisors of each Party to whom any
such Confidential Information is entrusted comply with these restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Loan Agreement</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; width: 10%; font-size: 10pt">3/4</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">The term Confidential Information
shall not include any information: (i) which as of the time of its disclosure by a Party was already lawfully in the possession of the
receiving Party as evidenced by written records, or (ii) which at the time of the disclosure was in the public domain, or (iii) the disclosure
of which was previously explicitly authorized by the respective Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">The non-disclosure obligation
shall not apply to any disclosure of Confidential Information required by law or regulations. In the event a disclosure of Confidential
Information is required by law or regulations (including, without limitation, for tax, audit or regulatory purposes), the disclosing Party
shall use all reasonable efforts to arrange for the confidential treatment of the materials and information so disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">Each Party may use any Confidential
Information in accordance with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><B>6.2.</B></TD><TD STYLE="text-align: justify"><B>Notices</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">Any communication to be made
under or in connection with this Agreement shall be made in writing and made by letter or e-mail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">Each Party may change or
amend the addresses given on the cover page or designate additional addresses for the purposes of this Section 6.2
by giving the other Parties written notice of the new address in the manner set forth in this Section 6.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><B>6.3.</B></TD><TD STYLE="text-align: justify"><B>Entire Agreement</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">The Agreement constitutes the
entire agreement among the Parties and supersede any prior understandings, agreements or representations by or among the Parties, or any
of them, written or oral, with respect to the subject matter of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><B>6.4.</B></TD><TD STYLE="text-align: justify"><B>Partial Invalidity</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">If at any time any provision
of the Agreement or any part thereof is or becomes invalid or unenforceable, then neither the validity nor the enforceability of the remaining
provisions or the remaining part of the provision shall in any way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">The Parties agree to replace
the invalid or unenforceable provision or part thereof by a valid or enforceable provision which shall best reflect the Parties&rsquo; original
intention and shall to the extent possible achieve the same economic result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><B>6.5.</B></TD><TD STYLE="text-align: justify"><B>Waiver of Rights</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">No waiver by a Party of
a failure of any other Party to perform any provision of this Agreement shall operate or be construed as a waiver in respect of any other
or further failure whether of a similar or different character.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><B>6.6.</B></TD><TD STYLE="text-align: justify"><B>Counterparts</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">The Agreement may be executed
in any number of counterparts, and this has the same effect as if the signatures on the counterparts were on a single copy of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Loan Agreement</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; width: 10%; font-size: 10pt">4/4</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 19.7pt">7.</TD><TD STYLE="text-align: justify">Governing law and Jurisdiction</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><B>7.1.</B></TD><TD STYLE="text-align: justify"><B>Governing Law</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">This Agreement shall in all
respects be governed by and construed in accordance with the substantive laws of Swiss law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in"><B>7.2.</B></TD><TD STYLE="text-align: justify"><B>Jurisdiction</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left">All disputes arising out
of or in connection with this Agreement, including disputes regarding its conclusion, validity, binding effect, amendment, breach, termination
or rescission shall be subject to the exclusive jurisdiction of the ordinary courts of Zurich, canton of Zurich, Switzerland, venue being
Zurich 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><B>IN WITNESS WHEREOF</B>, the Parties have signed this
Agreement on the date first written above</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;&nbsp;&nbsp;</TD>
  <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>[&nbsp;&nbsp;]</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">NLS Pharmaceutics AG</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%">Name:</TD>
    <TD STYLE="width: 32%">Alex Zwyer</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 8%">Name:</TD>
    <TD STYLE="width: 32%"></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Function:&nbsp;</TD>
    <TD>CEO</TD>
    <TD>&nbsp;</TD>
    <TD>Function:&nbsp;</TD>
    <TD></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea188582ex99-2_nlspharma.htm
<DESCRIPTION>PRESS RELEASE TITLED: NLS PHARMACEUTICS ANNOUNCES SELECTION OF STRATEGIC PARTNER AND SECURING A BRIDGE LOAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-2_001.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NLS Pharmaceutics Announces</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Selection of Strategic
Partner and Securing a Bridge Loan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><I>NLS has executed a non-binding term sheet for licensing
of NLS intellectual property</I></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><I>NLS has secured an additional bridge loan through insiders
to extend cash runway</I></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><I>NLS has implemented significant internal cost reductions</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>Z&uuml;rich, Switzerland,
November 16, 2023</B></FONT> &ndash; NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (&ldquo;NLS&rdquo; or the &ldquo;Company&rdquo;), a
Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare
and complex central nervous system disorders, today announced that it is conducting an ongoing process to explore strategic alternatives
to maximize shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">In response to the ever-evolving
biotech and pharmaceutical landscape and driven by a commitment to innovation, NLS has initiated a comprehensive exploration of new opportunities
that align with its core values and strengths. This strategic move aims to diversify NLS revenue streams, mitigate risks, and create lasting
value for our stakeholders. As part of this process, the Company plans to consider a wide range of options with a focus on maximizing
shareholder value, including strategic partnerships, outlicensing assets of the Company, and other future strategic actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Initial steps taken:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;<FONT STYLE="font-family: Symbol"></FONT></TD><TD STYLE="text-align: left">NLS Pharmaceutics has selected a strategic partner and executed
a non-binding term sheet for the outlicensing of its intellectual property, including its key asset Mazindol. The financial terms of
the term sheet have not yet been finalized. The Company intends to close this transaction in the first quarter of 2024.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;<FONT STYLE="font-family: Symbol"></FONT></TD><TD STYLE="text-align: left">NLS has secured additional bridge financing in the amount
of approximately $1 million USD to extend the Company&rsquo;s cash runway until the second quarter of 2024. The bridge financing has
been provided by company insiders, including Ronald Hafner, the Company&rsquo;s Chairman, Felix Grisard, J&uuml;rgen Bauer and Maria
Nayvalt. Such bridge loans will mature upon the earlier of June 30, 2024 or a liquidity event with a strategic partner. NLS previously
received a bridge loan of 500,000 CFH from Mr. Hafner , which has also been extended to to mature at the same time as the second loan,
or until June 30, 2024.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;<FONT STYLE="font-family: Symbol"></FONT></TD><TD STYLE="text-align: left">In conjunction with the ongoing strategic process, NLS has
implemented a workforce reduction of approximately 50%. This includes a pause on consulting agreements, reduction in non-clinical staff,
reduction in non-esstential operating expenses.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Alex Zwyer, CEO and
Co-Founder of NLS Pharmaceutics notes, &ldquo;We invite stakeholders, customers and partners to follow our journey as we explore new
opportunities now and in the coming months. Regular updates and progress reports will be shared to keep everyone informed about the
exciting developments stemming from this strategic exploration.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">NLS remains committed to maintaining the highest standards of
quality and integrity throughout this exploration process. The Company&rsquo;s leadership is confident that these strategic initiatives
will not only contribute to sustainable growth but also fortify our position as an emerging leader in innovative therapies for
patients with rare and complex central nervous system disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>About NLS Pharmaceutics Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">NLS Pharmaceutics Ltd. (Nasdaq:
NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized
scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system
disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team
with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><B>Safe Harbor Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">This press release contains expressed
or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when
it discusses the potential for the licensing transaction pursuant to the non-binding term sheet, the expected closing of the licensing
transaction, its expected cash runway and that its leadership is confident that these strategic initiatives will not only contribute to
sustainable growth but also fortify its position as an emerging leader in innovative therapies for patients with rare and complex central
nervous system disorders. These forward-looking statements and their implications are based on the current expectations of the management
of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described
in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described
in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or
successfully completing its clinical trials; NLS&rsquo; products may not be approved by regulatory agencies, NLS&rsquo; technology may not be validated
as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees
whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS&rsquo; process; NLS&rsquo;
products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in
real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS&rsquo; patents may not
be sufficient; NLS&rsquo; products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce
new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could
cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except
as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect
events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the
risks and uncertainties affecting NLS is contained under the heading &ldquo;Risk Factors&rdquo; in NLS&rsquo; annual report on Form 20-F for the
year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC), which is available on the SEC&rsquo;s website, www.sec.gov,
and in subsequent filings made by NLS with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><B>For additional information:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Marianne Lambertson (investors &amp; media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">NLS Pharmaceutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">ml@nls-pharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">www.nls-pharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- 48# 2(  A$! Q$!_\0
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M-KNS LJ^P]/>NOK&I;FT-Z,9*%I/4S]=_P"1?U'_ *]I/_037EEA%/X>\/\
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04%%%%(H**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
